• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同类型子宫内膜癌发病率上升的差异趋势:来自英国 1994 年至 2006 年基于人群的登记处的数据。

Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006.

机构信息

West Midlands Cancer Intelligence Unit, University of Birmingham, Birmingham B15 2TT, UK.

出版信息

Br J Cancer. 2011 Apr 26;104(9):1505-10. doi: 10.1038/bjc.2011.68.

DOI:10.1038/bjc.2011.68
PMID:21522151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3101940/
Abstract

BACKGROUND

Endometrial cancer is the most common gynaecological cancer in the western world, the incidence increasing in the United Kingdom by over 40% since 1993. Two types of endometrial cancer exist - oestrogen-dependent type 1 with good prognosis and non-oestrogen-dependent type 2 with poor prognosis. The histopathological distribution of the increase in endometrial cancer is unknown. This study investigates the observed incidence trends of the two types, the age, stage, and socioeconomic distribution of this increase and survival outcome.

METHODS

Data were analysed from 6867 women with endometrial cancer registered between 1994 and 2006, at a UK population-based cancer registry.

RESULTS

Increased endometrial cancer incidence is confined to type 1 cancers with a significant increase in age standardised incidence rate (ASR) from 12.0 per 100,000 (confidence interval (CI) 10.7-13.2) in 1994 to 16.3 per 100,000 (CI 14.9-17.7), P<0.001 in 2006, while ASR of type 2 cancer changed from 2.5 per 100,000 (CI 2.0-3.1) in 1994 to 2.2 per 100,000 (CI 1.7-2.7) in 2006, which was not statistically significant P>0.05. Increase in type 1 cancer is most marked in age groups 60-69 years (P<0.001) and 70-79 years (P<0.001) and distributed equally among socioeconomic quintiles. While outcome for type 1 cancer has improved, 1-year survival in type 2 cancer is unchanged from 73.1% in 1994 to 74.3%, P=0.089 and 5-year survival decreased from 55.1% to 40.9%, P=0.001.

CONCLUSION

Increased incidence in endometrial cancer is confined to type 1 cancers, seen most in the 60-79 age groups and across all socioeconomic quintiles. Survival in type 2 cancer has decreased significantly. Urgent research is needed to investigate prevention strategies in type 1 and improve therapy in type 2 cancers.

摘要

背景

子宫内膜癌是西方世界最常见的妇科癌症,自 1993 年以来,英国的发病率上升了 40%以上。存在两种类型的子宫内膜癌——雌激素依赖性 1 型预后良好,非雌激素依赖性 2 型预后不良。子宫内膜癌的组织病理学分布增加尚不清楚。本研究调查了这两种类型的观察到的发病率趋势、这种增加的年龄、阶段和社会经济分布以及生存结果。

方法

对英国基于人群的癌症登记处 1994 年至 2006 年间登记的 6867 名子宫内膜癌女性患者的数据进行了分析。

结果

子宫内膜癌发病率的增加仅限于 1 型癌症,年龄标准化发病率(ASR)从 1994 年的每 100,000 人 12.0(置信区间 10.7-13.2)显著增加到 2006 年的每 100,000 人 16.3(置信区间 14.9-17.7),P<0.001,而 2 型癌症的 ASR 从 1994 年的每 100,000 人 2.5(置信区间 2.0-3.1)变为 2006 年的每 100,000 人 2.2(置信区间 1.7-2.7),差异无统计学意义(P>0.05)。1 型癌症的增加在 60-69 岁(P<0.001)和 70-79 岁(P<0.001)年龄组最为明显,并且在社会经济五分位数中分布均匀。尽管 1 型癌症的治疗结果有所改善,但 2 型癌症的 1 年生存率仍保持不变,从 1994 年的 73.1%到 74.3%,P=0.089,5 年生存率从 55.1%降至 40.9%,P=0.001。

结论

子宫内膜癌发病率的增加仅限于 1 型癌症,在 60-79 岁年龄组和所有社会经济五分位数中均可见。2 型癌症的生存率显著下降。迫切需要研究 1 型癌症的预防策略,并改善 2 型癌症的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e2/3101940/9afe14e845fa/bjc201168f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e2/3101940/c85a305619f1/bjc201168f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e2/3101940/9afe14e845fa/bjc201168f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e2/3101940/c85a305619f1/bjc201168f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5e2/3101940/9afe14e845fa/bjc201168f4.jpg

相似文献

1
Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006.不同类型子宫内膜癌发病率上升的差异趋势:来自英国 1994 年至 2006 年基于人群的登记处的数据。
Br J Cancer. 2011 Apr 26;104(9):1505-10. doi: 10.1038/bjc.2011.68.
2
Childhood body mass index and height and risk of histologic subtypes of endometrial cancer.儿童体重指数、身高与子宫内膜癌组织学亚型风险
Int J Obes (Lond). 2016 Jul;40(7):1096-102. doi: 10.1038/ijo.2016.56. Epub 2016 Apr 28.
3
Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008.1989-2008 年荷兰罕见子宫体恶性肿瘤的发病和生存趋势。
Int J Gynecol Cancer. 2012 May;22(4):599-606. doi: 10.1097/IGC.0b013e318244cedc.
4
International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013.国际子宫内膜癌发病率的模式和趋势,1978-2013 年。
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361. doi: 10.1093/jnci/djx214.
5
Endometrial cancer in Olmsted County, MN: trends in incidence, risk factors and survival.明尼苏达州奥尔姆斯特德县的子宫内膜癌:发病率、风险因素及生存趋势
Ann Epidemiol. 2000 Feb;10(2):97-105. doi: 10.1016/s1047-2797(99)00039-3.
6
Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978-1998.意大利翁布里亚地区的妇科癌症:1978 - 1998年发病率、死亡率及生存率趋势
Eur J Obstet Gynecol Reprod Biol. 2004 Jul 15;115(1):59-65. doi: 10.1016/j.ejogrb.2003.11.026.
7
The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.澳大利亚可预防的子宫内膜癌和卵巢癌负担:一项汇总队列研究。
Gynecol Oncol. 2019 Jun;153(3):580-588. doi: 10.1016/j.ygyno.2019.03.102. Epub 2019 Mar 29.
8
Ovarian and endometrial cancers.卵巢癌和子宫内膜癌。
Cancer Surv. 1994;19-20:287-307.
9
Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.乳腺癌治疗后子宫内膜癌的生存情况与他莫昔芬治疗的关系:三个国家的汇总结果。
Breast Cancer Res. 2012 Jun 12;14(3):R91. doi: 10.1186/bcr3206.
10
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.

引用本文的文献

1
Enhancing the therapeutic potential of FDA-approved ifosfamide and 5-fluorouracil through rational chemical modifications for endometrial cancer treatment.通过合理的化学修饰提高美国食品药品监督管理局批准的异环磷酰胺和5-氟尿嘧啶治疗子宫内膜癌的潜力。
Med Oncol. 2025 Jun 25;42(8):281. doi: 10.1007/s12032-025-02821-2.
2
Mismatch in testing: a retrospective analysis of mismatch repair testing in endometrial cancer and Lynch syndrome diagnosis in multiple specialist centres in the UK and Ireland (March 2022-March 2023).检测中的不匹配:对英国和爱尔兰多个专科中心子宫内膜癌错配修复检测及林奇综合征诊断的回顾性分析(2022年3月 - 2023年3月)
BMJ Oncol. 2025 Jun 9;4(1):e000688. doi: 10.1136/bmjonc-2024-000688. eCollection 2025.
3

本文引用的文献

1
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
2
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.澳大利亚、加拿大、丹麦、挪威、瑞典和英国的癌症生存状况,1995-2007 年(国际癌症基准合作):基于人群的癌症登记数据分析。
Lancet. 2011 Jan 8;377(9760):127-38. doi: 10.1016/S0140-6736(10)62231-3. Epub 2010 Dec 21.
3
Patterns of care for European colorectal cancer patients diagnosed 1996-1998: a EUROCARE high resolution study.
Expression, Distribution and Function of the Transient Receptor Potential Vanilloid Type 1 (TRPV1) in Endometrial Cancer.
瞬时受体电位香草酸亚型1(TRPV1)在子宫内膜癌中的表达、分布及功能
Int J Mol Sci. 2025 Mar 27;26(7):3104. doi: 10.3390/ijms26073104.
4
Trends of endometrial cancer incidence in Sri Lanka from 2011 to 2020: An analysis of annual national cancer incidence data reports.2011年至2020年斯里兰卡子宫内膜癌发病率趋势:全国年度癌症发病率数据报告分析
J Family Med Prim Care. 2024 Aug;13(8):3304-3308. doi: 10.4103/jfmpc.jfmpc_1990_23. Epub 2024 Jul 26.
5
The efficacy and safety of the novel combination lenvatinib and pembrolizumab in endometrial cancer: A systematic review and single-arm meta-analysis.新型组合乐伐替尼和帕博利珠单抗治疗子宫内膜癌的疗效与安全性:一项系统评价和单臂荟萃分析。
Heliyon. 2024 Apr 25;10(9):e30257. doi: 10.1016/j.heliyon.2024.e30257. eCollection 2024 May 15.
6
Sociodemographic, clinical characteristics, and treatment patterns of endometrial cancer cases in Puerto Rico during the period 2009 to 2015: A retrospective study.波多黎各 2009 年至 2015 年期间子宫内膜癌病例的社会人口学、临床特征和治疗模式:一项回顾性研究。
PLoS One. 2024 May 2;19(5):e0302253. doi: 10.1371/journal.pone.0302253. eCollection 2024.
7
Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial.树突状细胞疫苗联合卡铂/紫杉醇治疗转移性子宫内膜癌患者的 I/II 期试验结果。
Front Immunol. 2024 Feb 20;15:1368103. doi: 10.3389/fimmu.2024.1368103. eCollection 2024.
8
Trends in the incidence and survival outcomes of endometrial cancer in Korea: a nationwide population-based cohort study.韩国子宫内膜癌发病率和生存结局的趋势:一项全国基于人群的队列研究。
J Gynecol Oncol. 2024 May;35(3):e32. doi: 10.3802/jgo.2024.35.e32. Epub 2023 Dec 19.
9
Surgical Staging of Differentiated Endometrial Cancer: An Analysis of Postoperative Outcome in a Gynecological Cancer Center in Sri Lanka.子宫内膜样腺癌的手术分期:斯里兰卡一家妇科癌症中心的术后结果分析
Cureus. 2023 Jul 9;15(7):e41605. doi: 10.7759/cureus.41605. eCollection 2023 Jul.
10
Prognostic factors in endometrial cancer patients with bone metastasis.子宫内膜癌骨转移患者的预后因素。
Jt Dis Relat Surg. 2023;34(1):207-214. doi: 10.52312/jdrs.2023.792. Epub 2023 Jan 6.
1996-1998 年确诊的欧洲结直肠癌患者的治疗模式:一项 EUROCARE 高分辨率研究。
Acta Oncol. 2010 Aug;49(6):776-83. doi: 10.3109/02841861003782009.
4
Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027.挪威 1953-2007 年子宫内膜癌发病趋势及 2008-2027 年预测。
Int J Cancer. 2010 Dec 1;127(11):2661-8. doi: 10.1002/ijc.25267.
5
The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis.欧洲癌症生存情况EUROCARE-4数据库:数据标准化、质量控制及统计分析方法
Eur J Cancer. 2009 Apr;45(6):909-30. doi: 10.1016/j.ejca.2008.11.003. Epub 2009 Jan 6.
6
Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.子宫体非子宫内膜样腺癌:特定组织学亚型综述
Cancer Control. 2009 Jan;16(1):46-52. doi: 10.1177/107327480901600107.
7
The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.子宫内膜癌的分子生物学及其对发病机制、分类和靶向治疗的意义。
Cancer Control. 2009 Jan;16(1):8-13. doi: 10.1177/107327480901600102.
8
Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.子宫内膜癌的分子病理学:从诊断和治疗角度的实践要点
J Clin Pathol. 2009 Sep;62(9):777-85. doi: 10.1136/jcp.2008.056101. Epub 2008 Oct 31.
9
Survival from endometrial cancer in England and Wales up to 2001.截至2001年英格兰和威尔士子宫内膜癌患者的生存率。
Br J Cancer. 2008 Sep 23;99 Suppl 1(Suppl 1):S68-9. doi: 10.1038/sj.bjc.6604592.
10
Survival from cancer of the uterus in England and Wales up to 2001.截至2001年英格兰和威尔士子宫癌患者的生存率。
Br J Cancer. 2008 Sep 23;99 Suppl 1(Suppl 1):S65-7. doi: 10.1038/sj.bjc.6604591.